RECURSION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.42 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $4.59, a 28.39% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $6.41, a 20.49% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $5.32, a 28.30% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $7.42, a 182.13% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $4.42, a 21.63% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.64, a 0.00% change from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $5.64, a 14.16% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $6.57, a 14.23% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.42 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $4.47 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $4.47 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $4.59 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $5.64 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $5.88 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $6.35 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $6.41 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $5.64 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $5.64 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $5.55 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $5.32 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $6.57 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $6.57 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $6.57 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $7.42 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $7.66 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $6.41 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $5.96 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $2.63 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $1.50 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $1.49 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $1.49 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $1.33 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $1.34 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |